Aptamer Therapeutics collaborates with Cancer Research UK for drug development program

Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukemia Research Program at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as therapeutic agents for the treatment of Chronic Myelomonocytic Leukemia (CMML) and other myeloid malignancies.

Aptamers are synthetic alternatives to antibodies that can be designed as therapeutics to disrupt disease targets and pathways.

The partnership intends to build on the initial data showing aptamers with therapeutic potential that can selectively target a key gene fault involved in driving this group of cancers.

Tony Hickson, Cancer Research UK’s Chief Business Officer, said:

We’re thrilled to support this collaboration, building on excellence in drug discovery at the Cancer Research UK Manchester Institute. By bringing together the best minds in academic cancer research with the rigor and drive of industry partners, we can accelerate the development of potentially life-saving new treatments.”

The Cancer Research UK Biotherapeutic Drug Discovery Project Award aims to increase the availability of biotherapeutic drugs for the management of cancer. Aptamers are a relatively young technology, and this will allow the assessment of their potential in a wider therapeutic setting.

Arron Tolley, Aptamer Therapeutics’ Chief Executive Officer, said:

We are excited to partner with Cancer Research UK and the University of Manchester. This is further validation of the potential of our platform to generate therapeutic molecules for further development.”

Source: https://www.aptamergroup.co.uk/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2019, May 06). Aptamer Therapeutics collaborates with Cancer Research UK for drug development program. News-Medical. Retrieved on April 12, 2024 from https://www.news-medical.net/news/20190506/Aptamer-Therapeutics-collaborates-with-Cancer-Research-UK-for-drug-development-program.aspx.

  • MLA

    Aptamer Group. "Aptamer Therapeutics collaborates with Cancer Research UK for drug development program". News-Medical. 12 April 2024. <https://www.news-medical.net/news/20190506/Aptamer-Therapeutics-collaborates-with-Cancer-Research-UK-for-drug-development-program.aspx>.

  • Chicago

    Aptamer Group. "Aptamer Therapeutics collaborates with Cancer Research UK for drug development program". News-Medical. https://www.news-medical.net/news/20190506/Aptamer-Therapeutics-collaborates-with-Cancer-Research-UK-for-drug-development-program.aspx. (accessed April 12, 2024).

  • Harvard

    Aptamer Group. 2019. Aptamer Therapeutics collaborates with Cancer Research UK for drug development program. News-Medical, viewed 12 April 2024, https://www.news-medical.net/news/20190506/Aptamer-Therapeutics-collaborates-with-Cancer-Research-UK-for-drug-development-program.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test